Franzenburg, Kelli R.
Hansen, Rolf
Suett, Mark
Thompson, Stephen F.
Sergerie, Martin
Garcia, David
Margolese, Howard C.
Funding for this research was provided by:
Teva Canada
Article History
Received: 11 December 2024
Accepted: 30 May 2025
First Online: 16 July 2025
Declarations
:
: Kelli R. Franzenburg, Rolf Hansen, Mark Suett, Stephen F. Thompson, and Martin Sergerie are employees and shareholders of Teva Pharmaceuticals. David Garcia is an employee of EVERSANA, which provides commercialization services to the life sciences industry. Teva Pharmaceuticals contracted EVERSANA to complete this SLR and NMA. Howard C. Margolese received research grant support from AIFred, SyneuRx, and The Montreal General Hospital Foundation; speaker/consultation/ad board fees from AbbVie, Bausch Health, Boehringer Ingelheim, HLS Therapeutics, Lundbeck, Janssen, Newron, Otsuka, and Teva Pharmaceuticals.
: This article is based on previously conducted studies and does not contain any new studies with human participants performed by any of the authors.
: This article is licensed under a Creative Commons Attribution—Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative. Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view.a copy of this license, visit .